{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:34:36Z","timestamp":1787240076270,"version":"build-2736575974"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s11940-024-00797-4","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T22:01:26Z","timestamp":1719266486000},"page":"319-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Diagnosis and Management of Progressive Corticobasal Syndrome"],"prefix":"10.1007","volume":"26","author":[{"given":"Claire","family":"Delpirou Nouh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyan","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"797_CR1","first-page":"66","volume":"1","author":"VC Constantinides","year":"2019","unstructured":"Constantinides VC, Paraskevas GP, Paraskevas PG, Stefanis L, Kapaki E. Corticobasal degeneration and corticobasal syndrome: A review. Clin Park Relat Disord. 2019;1:66\u201371.","journal-title":"Clin Park Relat Disord"},{"key":"797_CR2","first-page":"23","volume":"92","author":"JJ Rebeiz","year":"1967","unstructured":"Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc. 1967;92:23\u20136.","journal-title":"Trans Am Neurol Assoc"},{"issue":"1","key":"797_CR3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneur.1968.00470310034003","volume":"18","author":"JJ Rebeiz","year":"1968","unstructured":"Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol. 1968;18(1):20\u201333.","journal-title":"Arch Neurol"},{"issue":"Pt 5","key":"797_CR4","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/brain\/112.5.1171","volume":"112","author":"WR Gibb","year":"1989","unstructured":"Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain. 1989;112(Pt 5):1171\u201392.","journal-title":"Brain"},{"issue":"9","key":"797_CR5","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1212\/WNL.53.9.1969","volume":"53","author":"DA Grimes","year":"1999","unstructured":"Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology. 1999;53(9):1969\u201374.","journal-title":"Neurology"},{"issue":"2","key":"797_CR6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1750-3639.1998.tb00159.x","volume":"8","author":"C Bergeron","year":"1998","unstructured":"Bergeron C, Davis A, Lang AE. Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline. Brain Pathol. 1998;8(2):355\u201365.","journal-title":"Brain Pathol"},{"issue":"4","key":"797_CR7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.1124","volume":"16","author":"NJ Cordato","year":"2001","unstructured":"Cordato NJ, Halliday GM, McCann H, Davies L, Williamson P, Fulham M, Morris JG. Corticobasal syndrome with tau pathology. Mov Disord. 2001;16(4):656\u201367.","journal-title":"Mov Disord"},{"issue":"1","key":"797_CR8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-510X(98)00221-4","volume":"160","author":"K Kaida","year":"1998","unstructured":"Kaida K, Takeda K, Nagata N, Kamakura K. Alzheimer\u2019s disease with asymmetric parietal lobe atrophy: a case report. J Neurol Sci. 1998;160(1):96\u20139.","journal-title":"J Neurol Sci"},{"issue":"4","key":"797_CR9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.52.4.879","volume":"52","author":"CL Barclay","year":"1999","unstructured":"Barclay CL, Bergeron C, Lang AE. Arm levitation in progressive supranuclear palsy. Neurology. 1999;52(4):879\u201382.","journal-title":"Neurology"},{"issue":"3","key":"797_CR10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1212\/WNL.46.3.720","volume":"46","author":"PJ Massman","year":"1996","unstructured":"Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer\u2019s disease. Neurology. 1996;46(3):720\u20136.","journal-title":"Neurology"},{"key":"797_CR11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.irn.2019.10.003","volume":"149","author":"G Respondek","year":"2019","unstructured":"Respondek G, Stamelou M, H\u00f6glinger GU. Classification of atypical parkinsonism per pathology versus phenotype. Int Rev Neurobiol. 2019;149:37\u201347.","journal-title":"Int Rev Neurobiol"},{"issue":"5","key":"797_CR12","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.25872","volume":"29","author":"JR Burrell","year":"2014","unstructured":"Burrell JR, Hodges JR, Rowe JB. Cognition in corticobasal syndrome and progressive supranuclear palsy: a review. Mov Disord. 2014;29(5):684\u201393.","journal-title":"Mov Disord"},{"issue":"4","key":"797_CR13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1212\/WNL.48.4.959","volume":"48","author":"JA Schneider","year":"1997","unstructured":"Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS. Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology. 1997;48(4):959\u201369.","journal-title":"Neurology"},{"issue":"1","key":"797_CR14","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1212\/WNL.0000000000009734","volume":"95","author":"N Sakae","year":"2020","unstructured":"Sakae N, Santos OA, Pedraza O, Litvan I, Murray ME, Duara R, et al. Clinical and pathologic features of cognitive-predominant corticobasal degeneration. Neurology. 2020;95(1):e35\u201345.","journal-title":"Neurology"},{"issue":"1","key":"797_CR15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1590\/1980-57642021dn15-010002","volume":"15","author":"IJ de Almeida","year":"2021","unstructured":"de Almeida IJ, Silagi ML, Parmera JB, Brucki SMD, Schochat E. Language in corticobasal syndrome: a systematic review. Dement Neuropsychol. 2021;15(1):16\u201327.","journal-title":"Dement Neuropsychol"},{"issue":"4","key":"797_CR16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1212\/01.WNL.0000081230.09863.ED","volume":"61","author":"NL Graham","year":"2003","unstructured":"Graham NL, Bak T, Patterson K, Hodges JR. Language function and dysfunction in corticobasal degeneration. Neurology. 2003;61(4):493\u20139.","journal-title":"Neurology"},{"issue":"8","key":"797_CR17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1590\/0004-282x20170077","volume":"75","author":"LM Oliveira","year":"2017","unstructured":"Oliveira LM, Barcellos I, Teive HAG, Munhoz RP. Cognitive dysfunction in corticobasal degeneration. Arq Neuropsiquiatr. 2017;75(8):570\u20139.","journal-title":"Arq Neuropsiquiatr"},{"issue":"7","key":"797_CR18","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s00415-011-6389-y","volume":"259","author":"S Luzzi","year":"2012","unstructured":"Luzzi S, Cafazzo V, Silvestrini M, Provinciali L, Pickering-Brown S, Mann D, Snowden JS. Semantic dementia associated with corticobasal syndrome: a further variant of frontotemporal lobe degeneration? J Neurol. 2012;259(7):1478\u201380.","journal-title":"J Neurol"},{"issue":"4","key":"797_CR19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061025","volume":"8","author":"JR Burrell","year":"2013","unstructured":"Burrell JR, Hornberger M, Villemagne VL, Rowe CC, Hodges JR. Clinical profile of PiB-positive corticobasal syndrome. PLoS ONE. 2013;8(4):e61025.","journal-title":"PLoS ONE"},{"issue":"7","key":"797_CR20","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jalz.2016.02.005","volume":"12","author":"F Di Stefano","year":"2016","unstructured":"Di Stefano F, Kas A, Habert MO, Decazes P, Lamari F, Lista S, et al. The phenotypical core of Alzheimer\u2019s disease-related and nonrelated variants of the corticobasal syndrome: A systematic clinical, neuropsychological, imaging, and biomarker study. Alzheimers Dement. 2016;12(7):786\u201395.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"797_CR21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1212\/WNL.0000000000000667","volume":"83","author":"CD Boyd","year":"2014","unstructured":"Boyd CD, Tierney M, Wassermann EM, Spina S, Oblak AL, Ghetti B, et al. Visuoperception test predicts pathologic diagnosis of Alzheimer disease in corticobasal syndrome. Neurology. 2014;83(6):510\u20139.","journal-title":"Neurology"},{"key":"797_CR22","doi-asserted-by":"crossref","unstructured":"Bluett B, Pantelyat AY, Litvan I, Ali F, Apetauerova D, Bega D, et al. Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: a consensus statement of the curepsp centers of care. Front Neurol. 2021;12:694872. Consensus guide developped to help approach the management of CBD and PSP.","DOI":"10.3389\/fneur.2021.694872"},{"key":"797_CR23","doi-asserted-by":"crossref","unstructured":"Jellinger KA. Pathomechanisms of cognitive and behavioral impairment in corticobasal degeneration. J Neural Transm (Vienna). 2023;130(12):1509\u201322. Review focusing on cognitive and behavioral abnormalities in CBD.","DOI":"10.1007\/s00702-023-02691-w"},{"issue":"4","key":"797_CR24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/practneurol-2020-002835","volume":"21","author":"D Wilson","year":"2021","unstructured":"Wilson D, Heron CL, Anderson T. Corticobasal syndrome: a practical guide. Pract Neurol. 2021;21(4):276\u201385.","journal-title":"Pract Neurol"},{"key":"797_CR25","doi-asserted-by":"crossref","unstructured":"Alster P, Madetko-Alster N, Migda A, Migda B, Kuty\u0142owski M, Kr\u00f3licki L, Friedman A. Sleep disturbances in progressive supranuclear palsy syndrome (PSPS) and corticobasal syndrome (CBS). Neurol Neurochir Pol. 2023;57(3):229\u201334. Detailed review on sleep disturbances in CBS and PSPS","DOI":"10.5603\/PJNNS.a2023.0019"},{"key":"797_CR26","doi-asserted-by":"crossref","unstructured":"Friedman JH, Thomas RJ. Catathrenia in possible progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat Disord. 2023;111:105414. Case reports and discussion on catathrenia as a possible occurence in CBS and PSPS","DOI":"10.1016\/j.parkreldis.2023.105414"},{"key":"797_CR27","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fneur.2018.00767","volume":"9","author":"T Yousaf","year":"2018","unstructured":"Yousaf T, Pagano G, Wilson H, Politis M. Neuroimaging of sleep disturbances in movement disorders. Front Neurol. 2018;9:767.","journal-title":"Front Neurol"},{"issue":"Pt 7","key":"797_CR28","first-page":"2045","volume":"133","author":"H Ling","year":"2010","unstructured":"Ling H, O\u2019Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation Brain. 2010;133(Pt 7):2045\u201357.","journal-title":"A clinicopathological re-evaluation Brain"},{"issue":"5","key":"797_CR29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496\u2013503.","journal-title":"Neurology"},{"key":"797_CR30","doi-asserted-by":"crossref","unstructured":"Shir D, Pham NTT, Botha H, Koga S, Kouri N, Ali F, et al. Clinicoradiologic and neuropathologic evaluation of corticobasal syndrome. Neurology. 2023;101(3):e289\u201399. Review of clinicoradiologic and neuropathologic findings in a large CBS cohort with pathology-proven diagnosis.","DOI":"10.1212\/WNL.0000000000207397"},{"key":"797_CR31","doi-asserted-by":"crossref","unstructured":"Aiba I, Hayashi Y, Shimohata T, Yoshida M, Saito Y, Wakabayashi K, et al. Clinical course of pathologically confirmed corticobasal degeneration and corticobasal syndrome. Brain Commun. 2023;5(6):fcad296. Clinical findings in a CBS cohort with neuropathological correlations","DOI":"10.1093\/braincomms\/fcae028"},{"key":"797_CR32","doi-asserted-by":"crossref","unstructured":"Madetko N, Marzec W, Kowalska A, Przewodowska D, Alster P, Koziorowski D. Anti-IgLON5 disease - the current state of knowledge and further perspectives. Front Immunol. 2022;13:852215. Review summarizing the current state of knowledge on anti-IgLON5 disease.","DOI":"10.3389\/fimmu.2022.852215"},{"key":"797_CR33","doi-asserted-by":"crossref","unstructured":"Hermann P, Zerr I. Rapidly progressive dementias - aetiologies, diagnosis and management. Nat Rev Neurol. 2022;18(6):363\u201376. Recent review on RPD diverse etiologies, diagnosis process an therapeutic options","DOI":"10.1038\/s41582-022-00659-0"},{"issue":"5","key":"797_CR34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/mdc3.12957","volume":"7","author":"K Fuseya","year":"2020","unstructured":"Fuseya K, Kimura A, Yoshikura N, Yamada M, Hayashi Y, Shimohata T. Corticobasal syndrome in a patient with anti-IgLON5 antibodies. Mov Disord Clin Pract. 2020;7(5):557\u20139.","journal-title":"Mov Disord Clin Pract"},{"key":"797_CR35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2019.09.001","volume":"68","author":"S Koga","year":"2019","unstructured":"Koga S, Roemer SF, Kasanuki K, Dickson DW. Cerebrovascular pathology presenting as corticobasal syndrome: An autopsy case series of \u201cvascular CBS.\u201d Parkinsonism Relat Disord. 2019;68:79\u201384.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"797_CR36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrneurol.2011.43","volume":"7","author":"N Kouri","year":"2011","unstructured":"Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011;7(5):263\u201372.","journal-title":"Nat Rev Neurol"},{"key":"797_CR37","doi-asserted-by":"crossref","unstructured":"Koga S, Josephs KA, Aiba I, Yoshida M, Dickson DW. Neuropathology and emerging biomarkers in corticobasal syndrome. J Neurol Neurosurg Psychiatry. 2022;93(9):919\u201329. Comprehensive review of the neuropathology of CBS.","DOI":"10.1136\/jnnp-2021-328586"},{"issue":"2","key":"797_CR38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.22424","volume":"70","author":"SE Lee","year":"2011","unstructured":"Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327\u201340.","journal-title":"Ann Neurol"},{"issue":"23","key":"797_CR39","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1073\/pnas.1301175110","volume":"110","author":"F Clavaguera","year":"2013","unstructured":"Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA. 2013;110(23):9535\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 12","key":"797_CR40","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/brain\/aww256","volume":"139","author":"H Ling","year":"2016","unstructured":"Ling H, Kovacs GG, Vonsattel JP, Davey K, Mok KY, Hardy J, et al. Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain. 2016;139(Pt 12):3237\u201352.","journal-title":"Brain"},{"issue":"5","key":"797_CR41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1440-1789.2006.00669.x","volume":"26","author":"K Arima","year":"2006","unstructured":"Arima K. Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies. Neuropathology. 2006;26(5):475\u201383.","journal-title":"Neuropathology"},{"issue":"1","key":"797_CR42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/mds.27872","volume":"35","author":"G Respondek","year":"2020","unstructured":"Respondek G, Grimm MJ, Piot I, Arzberger T, Compta Y, Englund E, et al. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord. 2020;35(1):171\u20136.","journal-title":"Mov Disord"},{"key":"797_CR43","doi-asserted-by":"crossref","unstructured":"Fiock KL, Hook JN, Hefti MM. Determinants of astrocytic pathology in stem cell models of primary tauopathies. Acta Neuropathol Commun. 2023;11(1):161. Study focusing on\u00a0determining the origins of astrocytic tau in 4R tauopathies.","DOI":"10.1186\/s40478-023-01655-1"},{"key":"797_CR44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fnagi.2020.00096","volume":"12","author":"GG Kovacs","year":"2020","unstructured":"Kovacs GG. Astroglia and Tau: New Perspectives. Front Aging Neurosci. 2020;12:96.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"797_CR45","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/neup.12108","volume":"34","author":"T Uchihara","year":"2014","unstructured":"Uchihara T. Pretangles and neurofibrillary changes: similarities and differences between AD and CBD based on molecular and morphological evolution. Neuropathology. 2014;34(6):571\u20137.","journal-title":"Neuropathology"},{"issue":"4","key":"797_CR46","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00401-016-1591-8","volume":"132","author":"E Gelpi","year":"2016","unstructured":"Gelpi E, H\u00f6ftberger R, Graus F, Ling H, Holton JL, Dawson T, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol. 2016;132(4):531\u201343.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"797_CR47","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000136","volume":"2","author":"MM Simabukuro","year":"2015","unstructured":"Simabukuro MM, Sabater L, Adoni T, Cury RG, Haddad MS, Moreira CH, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e136.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"797_CR48","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/WNL.56.12.1702","volume":"56","author":"H Houlden","year":"2001","unstructured":"Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56(12):1702\u20136.","journal-title":"Neurology"},{"issue":"3","key":"797_CR49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1468-1331.2008.02513.x","volume":"16","author":"AC Ludolph","year":"2009","unstructured":"Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009;16(3):297\u2013309.","journal-title":"Eur J Neurol"},{"issue":"7","key":"797_CR50","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41374-019-0197-x","volume":"99","author":"KH Strang","year":"2019","unstructured":"Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Invest. 2019;99(7):912\u201328.","journal-title":"Lab Invest"},{"issue":"1","key":"797_CR51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/cells10010171","volume":"10","author":"F Arienti","year":"2021","unstructured":"Arienti F, Lazzeri G, Vizziello M, Monfrini E, Bresolin N, Saetti MC, Picillo M, Franco G, Di Fonzo A. Unravelling genetic factors underlying corticobasal syndrome: a systematic review. Cells. 2021;10(1):171.","journal-title":"Cells"},{"key":"797_CR52","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.702788","volume":"15","author":"B Boyarko","year":"2021","unstructured":"Boyarko B, Hook V. Human tau isoforms and proteolysis for production of toxic tau fragments in neurodegeneration. Front Neurosci. 2021;15:702788.","journal-title":"Front Neurosci"},{"key":"797_CR53","doi-asserted-by":"crossref","unstructured":"Shahpasand-Kroner H, Portillo J, Lantz C, Seidler PM, Sarafian N, Loo JA, Bitan G. Three-repeat and four-repeat tau isoforms form different oligomers. Protein Sci. 2022;31(3):613\u201327. Study looking at\u00a0tau oligomerization process.","DOI":"10.1002\/pro.4257"},{"issue":"11","key":"797_CR54","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/jmg.2005.031377","volume":"42","author":"AM Pittman","year":"2005","unstructured":"Pittman AM, Myers AJ, Abou-Sleiman P, Fung HC, Kaleem M, Marlowe L, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005;42(11):837\u201346.","journal-title":"J Med Genet"},{"key":"797_CR55","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wu KM, Yang L, Dong Q, Yu JT. Tauopathies: new perspectives and challenges. Mol Neurodegener. 2022;17(1):28. Review of the different types of tauopathies and prospective therapies.\u00a0","DOI":"10.1186\/s13024-022-00533-z"},{"issue":"6","key":"797_CR56","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1212\/NXI.0000000000000605","volume":"6","author":"C Gaig","year":"2019","unstructured":"Gaig C, Ercilla G, Daura X, Ezquerra M, Fern\u00e1ndez-Santiago R, Palou E, Sabater L, H\u00f6ftberger R, Heidbreder A, H\u00f6gl B, Iranzo A, Santamaria J, Dalmau J, Graus F. HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e605.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"797_CR57","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00401-017-1693-y","volume":"133","author":"JS Yokoyama","year":"2017","unstructured":"Yokoyama JS, Karch CM, Fan CC, Bonham LW, Kouri N, Ross OA, et al. Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol. 2017;133(5):825\u201337.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"797_CR58","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13554794.2021.1879869","volume":"27","author":"J Rini","year":"2021","unstructured":"Rini J, Asken B, Geier E, Rankin K, Kramer J, Boxer A, et al. Genetic pleiotropy and the shared pathological features of corticobasal degeneration and progressive supranuclear palsy: a case report and a review of the literature. Neurocase. 2021;27(2):120\u20138.","journal-title":"Neurocase"},{"issue":"3","key":"797_CR59","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000334731","volume":"67","author":"HH Jung","year":"2012","unstructured":"Jung HH, Bremer J, Streffer J, Virdee K, Spillantini MG, Crowther RA, et al. Phenotypic variation of autosomal-dominant corticobasal degeneration. Eur Neurol. 2012;67(3):142\u201350.","journal-title":"Eur Neurol"},{"issue":"8","key":"797_CR60","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/01.wnl.0000240220.33950.0c","volume":"67","author":"A Rajput","year":"2006","unstructured":"Rajput A, Dickson DW, Robinson CA, Ross OA, D\u00e4chsel JC, Lincoln SJ, et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology. 2006;67(8):1506\u20138.","journal-title":"Neurology"},{"issue":"4","key":"797_CR61","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/mdc3.12212","volume":"2","author":"E Navarro","year":"2015","unstructured":"Navarro E, De Andr\u00e9s C, Guerrero C, Gim\u00e9nez-Rold\u00e1n S. Corticobasal syndrome in a family with early-onset Alzheimer\u2019s disease linked to a presenilin-1 gene mutation. Mov Disord Clin Pract. 2015;2(4):388\u201394.","journal-title":"Mov Disord Clin Pract"},{"issue":"7","key":"797_CR62","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/mdc3.13037","volume":"7","author":"F Abate","year":"2020","unstructured":"Abate F, Dati G, Ginevrino M, Valente EM, Barone P, Picillo M. APP-related corticobasal syndrome: expanding the list of corticobasal degeneration look alikes. Mov Disord Clin Pract. 2020;7(7):849\u201351.","journal-title":"Mov Disord Clin Pract"},{"issue":"11","key":"797_CR63","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1586\/ern.11.153","volume":"11","author":"A Hassan","year":"2011","unstructured":"Hassan A, Whitwell JL, Josephs KA. The corticobasal syndrome-Alzheimer\u2019s disease conundrum. Expert Rev Neurother. 2011;11(11):1569\u201378.","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"797_CR64","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/mds.23109","volume":"25","author":"A Alonso-Canovas","year":"2010","unstructured":"Alonso-Canovas A, Katschnig P, Tucci A, Carecchio M, Wood NW, Edwards M, et al. Atypical parkinsonism with apraxia and supranuclear gaze abnormalities in type 1 Gaucher disease. Expanding the spectrum: case report and literature review. Mov Disord. 2010;25(10):1506\u20139.","journal-title":"Mov Disord."},{"issue":"14","key":"797_CR65","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/mds.25229","volume":"27","author":"I Rubio-Agusti","year":"2012","unstructured":"Rubio-Agusti I, Kojovic M, Edwards MJ, Murphy E, Chandrashekar HS, Lachmann RH, Bhatia KP. Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review. Mov Disord. 2012;27(14):1769\u201374.","journal-title":"Mov Disord"},{"issue":"1","key":"797_CR66","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s40478-020-01097-z","volume":"8","author":"RR Valentino","year":"2020","unstructured":"Valentino RR, Koga S, Walton RL, Soto-Beasley AI, Kouri N, DeTure MA, et al. MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. Acta Neuropathol Commun. 2020;8(1):218.","journal-title":"Acta Neuropathol Commun"},{"key":"797_CR67","doi-asserted-by":"crossref","unstructured":"Dubois B, von Arnim CAF, Burnie N, Bozeat S, Cummings J. Biomarkers in Alzheimer\u2019s disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res Ther. 2023;15(1):175. Review of\u00a0different clinical phenotypes of AD and biomarkers.\u00a0","DOI":"10.1186\/s13195-023-01314-6"},{"key":"797_CR68","doi-asserted-by":"crossref","unstructured":"Bouwman FH, Frisoni GB, Johnson SC, Chen X, Engelborghs S, Ikeuchi T, et al. Clinical application of CSF biomarkers for Alzheimer\u2019s disease: from rationale to ratios. Alzheimers Dement (Amst). 2022;14(1):e12314. On the interest of using CSF AD biomarkers to\u00a0 improve diagnostic accuracy.","DOI":"10.1002\/dad2.12314"},{"key":"797_CR69","doi-asserted-by":"crossref","unstructured":"Alcolea D, Beeri MS, Rojas JC, Gardner RC, Lle\u00f3 A. Blood biomarkers in neurodegenerative diseases: implications for the clinical neurologist. Neurology. 2023;101(4):172\u201380. Discussing\u00a0blood-based biomarkers and future perspectives.\u00a0","DOI":"10.1212\/WNL.0000000000207193"},{"key":"797_CR70","doi-asserted-by":"crossref","unstructured":"Horie K, Barth\u00e9lemy NR, Spina S, VandeVrede L, He Y, Paterson RW, et al. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. Nat Med. 2022;28(12):2547\u201354. Study looking at\u00a0CSF MTBR-tau275 and MTBR-tau282 as potential biomarkers to aid in the diagnosis of primary tauopathies.","DOI":"10.1038\/s41591-022-02075-9"},{"issue":"1","key":"797_CR71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-020-0887-z","volume":"8","author":"MA Metrick 2nd","year":"2020","unstructured":"Metrick MA 2nd, Ferreira NDC, Saijo E, Kraus A, Newell K, Zanusso G, et al. A single ultrasensitive assay for detection and discrimination of tau aggregates of Alzheimer and Pick diseases. Acta Neuropathol Commun. 2020;8(1):22.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"797_CR72","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00401-019-02092-y","volume":"139","author":"E Saijo","year":"2020","unstructured":"Saijo E, Metrick MA 2nd, Koga S, Parchi P, Litvan I, Spina S, et al. Correction to: 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol. 2020;139(1):79\u201381.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"797_CR73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.psc.2020.02.006","volume":"43","author":"K Younes","year":"2020","unstructured":"Younes K, Miller BL. Frontotemporal dementia: neuropathology, genetics, neuroimaging, and treatments. Psychiatr Clin North Am. 2020;43(2):331\u201344.","journal-title":"Psychiatr Clin North Am"},{"key":"797_CR74","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a-Bautista C, Kumar R, Baquero M, Johansson J, Ch\u00e1fer-Peric\u00e1s C, Abelein A, Ferreira D. Misfolded alpha-synuclein detection by RT-QuIC in dementia with lewy bodies: a systematic review and meta-analysis. Front Mol Biosci. 2023;10:1193458. Meta-analysis on \u03b1-syn RT-QuIC as a biomarker in LBD.","DOI":"10.3389\/fmolb.2023.1193458"},{"issue":"2","key":"797_CR75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3988\/jcn.2019.15.2.135","volume":"15","author":"JY Kim","year":"2019","unstructured":"Kim JY, Illigens BM, McCormick MP, Wang N, Gibbons CH. Alpha-synuclein in skin nerve fibers as a biomarker for alpha-synucleinopathies. J Clin Neurol. 2019;15(2):135\u201342.","journal-title":"J Clin Neurol"},{"key":"797_CR76","doi-asserted-by":"crossref","unstructured":"Berger-Sieczkowski E, Endmayr V, Haider C, Ricken G, Jauk P, Macher S, et al. Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease. Acta Neuropathol. 2023;146(4):631\u201345. Retrospective study on\u00a0nine patients with anti-IgLON5 disease with clinical review and description of neuropathology\/tau-pathology.","DOI":"10.1007\/s00401-023-02625-6"},{"issue":"5","key":"797_CR77","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/ene.13928","volume":"26","author":"F Di Stasio","year":"2019","unstructured":"Di Stasio F, Suppa A, Marsili L, Upadhyay N, Asci F, Bologna M, et al. Corticobasal syndrome: neuroimaging and neurophysiological advances. Eur J Neurol. 2019;26(5):701-e52.","journal-title":"Eur J Neurol"},{"key":"797_CR78","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41531-017-0012-6","volume":"3","author":"F Albrecht","year":"2017","unstructured":"Albrecht F, Bisenius S, Morales Schaack R, Neumann J, Schroeter ML. Disentangling the neural correlates of corticobasal syndrome and corticobasal degeneration with systematic and quantitative ALE meta-analyses. NPJ Parkinsons Dis. 2017;3:12.","journal-title":"NPJ Parkinsons Dis"},{"issue":"5","key":"797_CR79","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.parkreldis.2014.01.023","volume":"20","author":"JL Whitwell","year":"2014","unstructured":"Whitwell JL, Schwarz CG, Reid RI, Kantarci K, Jack CR Jr, Josephs KA. Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat Disord. 2014;20(5):493\u20138.","journal-title":"Parkinsonism Relat Disord"},{"issue":"Pt 11","key":"797_CR80","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1093\/brain\/awu256","volume":"137","author":"M Niethammer","year":"2014","unstructured":"Niethammer M, Tang CC, Feigin A, Allen PJ, Heinen L, Hellwig S, et al. A disease-specific metabolic brain network associated with corticobasal degeneration. Brain. 2014;137(Pt 11):3036\u201346.","journal-title":"Brain"},{"issue":"5","key":"797_CR81","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3174\/ajnr.A4229","volume":"36","author":"MC Piattella","year":"2015","unstructured":"Piattella MC, Tona F, Bologna M, Sbardella E, Formica A, Petsas N, et al. Disrupted resting-state functional connectivity in progressive supranuclear palsy. AJNR Am J Neuroradiol. 2015;36(5):915\u201321.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"11","key":"797_CR82","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/jnnp-2014-308350","volume":"87","author":"RM Ahmed","year":"2016","unstructured":"Ahmed RM, Devenney EM, Irish M, Ittner A, Naismith S, Ittner LM, et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2016;87(11):1234\u201341.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"797_CR83","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrneurol.2014.178","volume":"10","author":"M Pievani","year":"2014","unstructured":"Pievani M, Filippini N, van den Heuvel MP, Cappa SF, Frisoni GB. Brain connectivity in neurodegenerative diseases\u2013from phenotype to proteinopathy. Nat Rev Neurol. 2014;10(11):620\u201333.","journal-title":"Nat Rev Neurol"},{"issue":"23","key":"797_CR84","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1212\/WNL.0b013e3181a96e5d","volume":"72","author":"B Meissner","year":"2009","unstructured":"Meissner B, Kallenberg K, Sanchez-Juan P, Collie D, Summers DM, Almonti S, et al. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology. 2009;72(23):1994\u20132001.","journal-title":"Neurology"},{"issue":"3","key":"797_CR85","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.25983","volume":"89","author":"A Bizzi","year":"2021","unstructured":"Bizzi A, Pascuzzo R, Blevins J, Moscatelli MEM, Grisoli M, Lodi R, et al. Subtype diagnosis of sporadic creutzfeldt-jakob disease with diffusion magnetic resonance imaging. Ann Neurol. 2021;89(3):560\u201372.","journal-title":"Ann Neurol"},{"issue":"6","key":"797_CR86","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/acn3.51290","volume":"8","author":"K Younes","year":"2021","unstructured":"Younes K, Rojas JC, Wolf A, Sheng-Yang GM, Paoletti M, Toller G, et al. Selective vulnerability to atrophy in sporadic Creutzfeldt-Jakob disease. Ann Clin Transl Neurol. 2021;8(6):1183\u201399.","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"797_CR87","doi-asserted-by":"crossref","first-page":"e1121","DOI":"10.1212\/WNL.0000000000007038","volume":"92","author":"M Pardini","year":"2019","unstructured":"Pardini M, Huey ED, Spina S, Kreisl WC, Morbelli S, Wassermann EM, et al. FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology. 2019;92(10):e1121\u201335.","journal-title":"Neurology"},{"issue":"1","key":"797_CR88","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13195-014-0093-y","volume":"7","author":"SJ Sha","year":"2015","unstructured":"Sha SJ, Ghosh PM, Lee SE, Corbetta-Rastelli C, Jagust WJ, Kornak J, et al. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimers Res Ther. 2015;7(1):8.","journal-title":"Alzheimers Res Ther"},{"key":"797_CR89","unstructured":"Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, et al. Prevalence estimates of amyloid abnormality across the alzheimer disease clinical spectrum. JAMA Neurol. 2022;79(3):228\u201343. Study assessing\u00a0amyloid abnormality in CSF and PET in participants with subjective cognitive decline, mild cognitive impairment, or clinical AD dementia."},{"key":"797_CR90","doi-asserted-by":"crossref","unstructured":"Messerschmidt K, Barthel H, Brendel M, Scherlach C, Hoffmann KT, Rauchmann BS, et al. (18)F-PI-2620 Tau PET improves the imaging diagnosis of progressive supranuclear palsy. J Nucl Med. 2022;63(11):1754\u201360. Study looking at place of\u00a018F-PI-2620 tau PET as a PSP biomarker and its possibility in improving imaging-based PSP diagnosis by adding 18F-PI-2620 tau PET to structural MRI.","DOI":"10.1055\/s-0041-1726747"},{"issue":"4","key":"797_CR91","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1021\/acschemneuro.0c00801","volume":"12","author":"A Lindberg","year":"2021","unstructured":"Lindberg A, Knight AC, Sohn D, Rakos L, Tong J, Radelet A, et al. Radiosynthesis, in vitro and in vivo evaluation of [(18)F]CBD-2115 as a first-in-class radiotracer for imaging 4R-tauopathies. ACS Chem Neurosci. 2021;12(4):596\u2013602.","journal-title":"ACS Chem Neurosci"},{"key":"797_CR92","doi-asserted-by":"crossref","unstructured":"Xiang J, Tao Y, Xia Y, Luo S, Zhao Q, Li B, et al. Development of an \u03b1-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell. 2023;186(16):3350\u201367.e19. Study looking at a promising PET tracer that shows\u00a0 preferential high binding affinity for \u03b1-Synuclein.","DOI":"10.1016\/j.cell.2023.06.004"},{"issue":"20","key":"797_CR93","doi-asserted-by":"crossref","first-page":"11234","DOI":"10.3390\/ijms222011234","volume":"22","author":"G Palermo","year":"2021","unstructured":"Palermo G, Giannoni S, Bellini G, Siciliano G, Ceravolo R. Dopamine transporter imaging, current status of a potential biomarker: a comprehensive review. Int J Mol Sci. 2021;22(20):11234.","journal-title":"Int J Mol Sci"},{"key":"797_CR94","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3389\/fneur.2019.01056","volume":"10","author":"MS Nissen","year":"2019","unstructured":"Nissen MS, Blaabjerg M. Anti-IgLON5 disease: a case with 11-year clinical course and review of the literature. Front Neurol. 2019;10:1056.","journal-title":"Front Neurol"},{"issue":"9","key":"797_CR95","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11940-016-0422-5","volume":"18","author":"R Lamb","year":"2016","unstructured":"Lamb R, Rohrer JD, Lees AJ, Morris HR. Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options. Curr Treat Options Neurol. 2016;18(9):42.","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"797_CR96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-0038-1677050","volume":"39","author":"S Rajan","year":"2019","unstructured":"Rajan S, Kaas B, Moukheiber E. Movement disorders emergencies. Semin Neurol. 2019;39(1):125\u201336.","journal-title":"Semin Neurol"},{"issue":"2","key":"797_CR97","doi-asserted-by":"crossref","first-page":"73","DOI":"10.14802\/jmd.11015","volume":"4","author":"MJ Lee","year":"2011","unstructured":"Lee MJ, Lyoo CH, Lee MS. Neuroleptic malignant syndrome in a patient with corticobasal degeneration. J Mov Disord. 2011;4(2):73\u20134.","journal-title":"J Mov Disord"},{"issue":"Suppl 1","key":"797_CR98","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.parkreldis.2015.09.023","volume":"22","author":"L Marsili","year":"2016","unstructured":"Marsili L, Suppa A, Berardelli A, Colosimo C. Therapeutic interventions in parkinsonism: Corticobasal degeneration. Parkinsonism Relat Disord. 2016;22(Suppl 1):S96-100.","journal-title":"Parkinsonism Relat Disord"},{"key":"797_CR99","doi-asserted-by":"crossref","unstructured":"Pantelyat A. Progressive supranuclear palsy and corticobasal syndrome. Continuum (Minneap Minn). 2022;28(5):1364\u201378. Review on PSP and CBD.\u00a0","DOI":"10.1212\/CON.0000000000001158"},{"issue":"9","key":"797_CR100","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/ene.12748","volume":"22","author":"M Bianchi","year":"2015","unstructured":"Bianchi M, Cosseddu M, Cotelli M, Manenti R, Brambilla M, Rizzetti MC, et al. Left parietal cortex transcranial direct current stimulation enhances gesture processing in corticobasal syndrome. Eur J Neurol. 2015;22(9):1317\u201322.","journal-title":"Eur J Neurol"},{"issue":"6","key":"797_CR101","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/cxo.12429","volume":"99","author":"RA Armstrong","year":"2016","unstructured":"Armstrong RA. Visual signs and symptoms of corticobasal degeneration. Clin Exp Optom. 2016;99(6):498\u2013506.","journal-title":"Clin Exp Optom"},{"key":"797_CR102","doi-asserted-by":"crossref","unstructured":"Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol. 2021;21(5):376\u201383. Review on PSP and management options.\u00a0","DOI":"10.1136\/practneurol-2020-002794"},{"issue":"2","key":"797_CR103","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","volume":"77","author":"RM Tsai","year":"2020","unstructured":"Tsai RM, Miller Z, Koestler M, Rojas JC, Ljubenkov PA, Rosen HJ, et al. Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial. JAMA Neurol. 2020;77(2):215\u201324.","journal-title":"JAMA Neurol"},{"key":"797_CR104","doi-asserted-by":"crossref","unstructured":"Kepp KP, Sensi SL, Johnsen KB, Barrio JR, H\u00f8ilund-Carlsen PF, Neve RL, et al. The anti-amyloid monoclonal antibody lecanemab: 16 cautionary notes. J Alzheimers Dis. 2023;94(2):497\u2013507. Discussion around the amyloid hypothesis controversy and words of caution about the new anti-amyloid therapies.","DOI":"10.3233\/JAD-230099"},{"issue":"3","key":"797_CR105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ana.26167","volume":"90","author":"N Moghavem","year":"2021","unstructured":"Moghavem N, Henderson VW, Greicius MD. Medicare should not cover aducanumab as a treatment for Alzheimer\u2019s disease. Ann Neurol. 2021;90(3):331\u20133.","journal-title":"Ann Neurol"},{"key":"797_CR106","doi-asserted-by":"crossref","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. Paper on the results of an 18-month, multicenter, double-blind, phase 3 clinical trial in early Alzheimer\u2019s disease with positive amyloid biomarkers (PET or CSF).","DOI":"10.1056\/NEJMoa2212948"},{"issue":"18","key":"797_CR107","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"key":"797_CR108","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327. Results of the phase 3 randomized clinical trial assessing donanemab efficacy and adverse events in\u00a0participants with early symptomatic Alzheimer disease."},{"key":"797_CR109","doi-asserted-by":"crossref","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377. Guidelines on how to safely use Lecanemab, including clinical features and screening tests for risk stratification, dosing and administration, then ARIA monitoring and management.","DOI":"10.14283\/jpad.2023.30"},{"key":"797_CR110","doi-asserted-by":"crossref","unstructured":"Cummings JL, Gonzalez MI, Pritchard MC, May PC, Toledo-Sherman LM, Harris GA. The therapeutic landscape of tauopathies: challenges and prospects. Alzheimers Res Ther. 2023;15(1):168. Comprehensive review on ongoing research and clinical trials targeting Tau pathology.","DOI":"10.1186\/s13195-023-01321-7"}],"updated-by":[{"DOI":"10.1007\/s11940-024-00805-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000}}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-024-00797-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-024-00797-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-024-00797-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:19:22Z","timestamp":1722313162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-024-00797-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":110,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s11940-024-00797-4","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"6 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11940-024-00805-7","URL":"https:\/\/doi.org\/10.1007\/s11940-024-00805-7","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}